Biotek-snakken — Juli 2024
-
Genovis: Strategic investment in developer of RNase inhibitors
https://www.redeye.se/research/1018575/genovis-strategic-investment-in-developer-of-rnase-inhibitors
(Redeye)
"Redeye comments on Genovis following the announcement of a strategic investment in SEQURNA, a developer of next-generation RNase inhibitors. Similar to the market, we positively view the announcement."
"The market trades the share up a few percent on the announcement, our base case remains at SEK65."
-
XBRANE PROVIDES UPDATE ON TIMING OF RE-SUBMISSION OF BLA FOR RANIBIZUMAB BIOSIMILAR CANDIDATE
" ... Should this submission be successful, this would result in a BsUFA date during the second quarter of 2025 assuming a standard 6 month review process and ongoing alignment with the FDA, as well as successful execution of remediation plans of the manufacturing partners."
-
Så begynder Cessatech at bevæge sig spændende på grafen - Kurs 7,0 er ramt i dag. Kan den holde sig på/over de 7 ved luk, burde det være stærkt støttesignal (se maj-sep 2022 perioden, hvor 7 var modstand). Fundamentalt hedder den markedslancering i disse uger i USA. Satser på en ganske positiv udvikling resten af året...og for den sags skyld også de næste par år...
-
BioArctic's Partner Eisai Says Leqembi Approved In Hong Kong For Alzheimer's Disease Treatment https://proinvestor.com/investornyt/1183677/bioarctics-partner-eisai-says-leqembi-approved-in-hong-kong-for-alzheimers-disease-treatment
-
ASCELIA PHARMA CARRIES OUT A RIGHTS ISSUE OF UNITS OF APPROXIMATELY SEK 105 MILLION TO FULLY FINANCE THE NDA SUBMISSION FOR ORVIGLANCE
Ascelia Pharma Carries Out a Rights Issue of Units of Approximately SEK 105 Million to Fully Finance the NDA Submission for Orviglance® – ASCELIA
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, ...
(www.ascelia.com)
-
Ascelia: Proceeds with a SEK 105m rights issue of units
-
" ... We regard this initiative as positive. Ascelia will be in a strong position to negotiate terms with a US partner, and the funding will dramatically reduce the financial uncertainty in Ascelia. The proposed funding will also allow Ascelia to focus on securing FDA approval for Orviglance and securing a US commercial partner on favourable terms."
-
BioArctic : Eisai's Leqembi Approved In Israel For Alzheimer's Disease Treatment https://proinvestor.com/investornyt/1184229/bioarctic-eisais-leqembi-approved-in-israel-for-alzheimers-disease-treatment
-
Immutep's Eftilagimod Alfa Combination Shows Positive Phase IIb Results In Head & Neck Cancer Trial https://proinvestor.com/investornyt/1184225/immuteps-eftilagimod-alfa-combination-shows-positive-phase-iib-results-in-head-amp-neck-cancer-trial
-
15 Healthcare Stocks Hit New Highs: Did You Spot These Winners? https://proinvestor.com/investornyt/1184904/15-healthcare-stocks-hit-new-highs-did-you-spot-these-winners
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind